Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors

The Phase 1/2 APOLLO global clinical trial evaluating CR-002 in multiple solid tumor types, including NSCLC and HNSCC, remains on track to initiate in Q4 2026. The update signals progress toward a clinical-stage evaluation but provides no efficacy results or other trial data.